3 november 2026 kl. 07:00(MFN)

NET ASSET VALUE – 31 October 2026

On the 31 October 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,102 million and NAV per share was SEK 34.72. Return on NAV per share in the month was -3.3%.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development
Lipum	100%	348	3.90	11.2%
Prokarium	50%	294	3.29	9.5%
Atrogi	47%	215	2.40	6.9%
KAHR Medical	34%	211	2.36	6.8%
Microbiotica	10%	189	2.12	6.1%
Bonsai Biotherapeutics	100%	158	1.76	5.1%
AnaCardio	9%	105	1.18	3.4%
Xspray Pharma	17%	93	1.04	3.0%
Xintela	60%	77	0.86	2.5%
Mendus	22%	72	0.80	2.3%
Geneos Therapeutics	12%	70	0.79	2.3%
EpiEndo Pharmaceuticals	9%	54	0.61	1.8%
Vitara Biomedical	9%	50	0.56	1.6%
Buzzard Pharmaceuticals	15%	33	0.37	1.1%
Goldcup 40330 (previously Biosergen)	100%	21	0.24	0.7%
Strike Pharma	29%	20	0.23	0.7%
Amarna Therapeutics	58%	11	0.12	0.4%
Total		2,022	22.63	65.2%

Commercial Growth
Symcel	30%	211	2.36	6.8%
NorthX Biologics	61%	202	2.26	6.5%
Chromafora	29%	149	1.67	4.8%
Nanologica	50%	27	0.30	0.9%
Frontier Biosolutions	2%	26	0.30	0.9%
Bohus Biotech	45%	22	0.25	0.7%
Total		637	7.13	20.5%

Assets and liabilities related to Portfolio companies		125	1.40	4.0%
Other assets and liabilities		318	3.56	10.2%

Net Asset Value		3,102	34.72	100.0%

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Bilagor & Media

Källa: MFN

0 kommentarer

Kommentera nyheten

När du kommenterar ett pressmeddelande publiceras din kommentar även i en speglad tråd under Börssnack så att alla i forumet kan delta i diskussionen!

Logga in eller skapa ett gratis konto för att kommentera nyheten!

Logga in Skapa konto